Replies to post #3085 on Pulmatrix Inc (PULM)

[riskon]

A very rare situation here imo, we have:
1) Company rooted in biodefense (military and civilian)
2) Langer(MIT)/Edwards(Harvard) cofounders & DARPA History
3) Edwards launching a spinoff of new form of Hygiene in FEND which he co-created/co-studied back in 2010
4) Partnership moving forward in large ways with Johnson and Johnson tackling COPD/Lung Cancer & More...
5) Partnership moving forward in large ways with CIPLA tackling
ABPA in Pulmazole
6) New PUR3100 product announced treating Migraines
7) Nocion Therapeutics Pain Research Collaboration
8) Approved by the FDA (USA) & MHRA (U.K.)
9) Mass Liscensing opportunities within
**Any Covid Vaccine (Inhaled Version --> shift to Dry Powder)
**Any Covid Therapeutics (oral capsules to inhalation)
**Any Vaccine (Tuberculosis --> shift to dry powder)
**Any therapeutic on the market (Higher efficacy, lower dosage)
10) Wildcards (Buyout by JNJ, Spinoffs, Etc.)

Historic opportunity here if Pulmatrix and Partners can deliver.

$PULM